ALG-1007 is a topical anti-integrin treatment in development for potential use in patients with dry eye disease. ALG-1007 demonstrated promising results in an ex-U.S. proof-of-concept clinical trial, in which it showed efficacy, a significant dose response curve, and that it was well-tolerated with no adverse events. A second and larger ex-U.S. Phase 2 clinical trial is underway with results anticipated in the second half of 2019.